### Other Names
- wilate®

### Pre-Transfusion Sample
- **☒ Not Required**
- **☐ Blood Group**
- **☐ Group & Screen**
- **☐ Crossmatch**

### Approval Requirements
Product must be ordered by clinical hematologist or Hemophilia Clinic Nurse Practitioner with required privileges.

### Product Description
Plasma derived, stable, highly purified concentrate of freeze-dried active human von Willebrand factor (VWF) and coagulation factor VIII (FVIII). Solvent detergent and heat treated to reduce viral transmission. Latex free. Supplied as a lyophilized product with sterile water diluent. Reconstituted and filtered into a syringe in Transfusion Medicine.

**Must be ordered in FVIII IU.**

Available vial sizes:
- 500 IU FVIII & 500 IU VWF
- 1000 IU FVIII & 1000 IU VWF

The ratio of FVIII and VWF in wilate® is 1:1

### Clinical Indications
- Treatment and prevention of bleeding episodes in patients with von Willebrand disease where the use of DDAVP treatment is ineffective or contra-indicated.
- Treatment and prophylaxis of bleeding in patients with hemophilia A who are at high risk of inhibitor development
- Immune tolerance induction in patients with Factor VIII inhibitors.

### Contraindications
- Patients with a known hypersensitivity to this drug or to any ingredient in the formulation or component of the container.

### Risks
- Allergic and anaphylactic reactions
- Formation of inhibitors to FVIII.
- As wilate® is a plasma product there is a risk for transmission of infection.
- Vaccination against hepatitis A and hepatitis B should be considered for patients who regularly receive FVIII/VWF concentrates.
- Wilate® should be administered to pregnant and lactating women only if clearly indicated.

### Dosage
Many patients carry a Factor First card with pertinent information about their prescribed therapy.
- Consult Hematologist or Nurse Practitioner for Inherited Blood Disorders for detailed dosing guidelines.
- The dosage must be individualized according to the needs of the patient.
- The nearest combination of whole vials must be used to deliver the prescribed dose.
**Administration**

| Administer the first ten doses of wilate® under **direct supervision** of RN/NP/MD |
| Encourage patient/caregiver to self-administer the product if they are knowledgeable and able to do so. |
| **Visually inspect** for particulate matter and discoloration prior to administration |
| **Refer** to: |
| • Administering Medications Using IV Push Method |
| • Product monograph |

**Administer:**

- By intravenous injection only
- At room temperature
- Through a separate injection site
- Inject slowly at a rate of 2-3 mL/minute.

**Compatible Solution**

The manufacturer does not recommend any compatible fluids. **Flush** the line before and after administration with 0.9% Normal Saline only. **Do not** mix with other medicinal products or intravenous admixtures.

**Infusion Rates**

**Maximum** injection rate is 2-3 mL/minute.

**Monitoring**

**Measure** heart rate before and during the injection. **Reduce** rate of injection if a marked increase in the heart rate occurs. **Stop and reevaluate** if the increase in heart rate persists despite slowing the injection rate. **Observe** patient for signs and symptoms of a transfusion reaction. In the event of a suspected transfusion reaction, refer to Transfusion Reaction Procedure & Quick Reference guide and complete Transfusion Reaction Report Form.

**Storage Conditions**

Stored at room temperature, not to exceed 25 C. Home storage of wilate® may vary from in hospital storage and does not apply in the hospital situation. 

**For reconstituted product:**

- Store at room temperature
- Administer immediately after reconstitution
- Return product and Transfusion Record to Transfusion Medicine within 20 minutes from time of issue if there are any delays in administration
- Do not refrigerate or store on nursing unit.

**References**